A Study of VEGF Tyrosine Kinase Inhibitor (Pazopanib) in Men With High-Risk Prostate Cancer Followed by Radical Prostatectomy and Pelvic Lymph Node Dissection

NCT01832259 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Adenocarcinoma of the Prostate

Interventions

DRUG: Pazopanib
OTHER: Placebo

Sponsor

University of Utah

Collaborators

[object Object]